Maxygen, Inc.
301 Galveston Drive
Redwood City,
CA 94063
United States - Map
Phone: 650-298-5300
Fax: 650-364-2715
Web Site: http://www.maxygen.com
| Maxygen, Inc., a biotechnology company, engages in the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. It primarily uses its MolecularBreeding directed evolution technology platform, along with ancillary technologies, to create proprietary proteins. The companys product candidates include MAXY-G34, which completed a Phase IIa clinical trial, is designed to be an improved next-generation pegylated, G-CSF for the treatment of neutropenia associated with cancer chemotherapy treatments; and MAXY-4 products that are designed to be CTLA-4 Ig therapeutics for the treatment of an array of autoimmune disorders, including rheumatoid arthritis. Its earlier stage programs in preclinical research include a preventative HIV vaccine. Maxygen, Inc. has a collaboration agreement with Astellas Pharma, Inc. for the development and commercialization of MAXY-4 product candidates for autoimmune diseases and transplant rejection; and a joint venture agreement to focus on the discovery, research, and development of multiple protein pharmaceutical programs, including MAXY-4 program and other early stage programs. The company was founded in 1996 and is headquartered in Redwood City, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Isaac Associates Stein , 62
Exec. Chairman and Chairman of Strategy Committee |
$
70.00K | N/A | Mr. James Sulat , 58
Chief Exec. Officer, Chief Financial Officer, Director, Chairman of Audit Committee, Member of Corp. Governance & Nominating Committee and Member of Strategy Committee |
$
51.00K | N/A | Mr. Grant Yonehiro , 45
Chief Bus. Officer and Sr. VP of Devel. Programs |
$
397.00K |
$
0 | Dr. Alan Shaw Ph.D., 45
Pres of Codexis Inc |
N/A
| N/A | Dr. Norman Kruse ,
Chief Patent Counsel and VP of Intellectual Property |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 0.00%
Profile
